Covid Testing Sites Continue as First Community Vaccination Sites Go Live for Florida Clinical Staffing Firm
Pulse Clinical Alliance, LLC, dba PCA, has been staffing Covid testing sites across Texas and Kansas since last year and is working with health officials to bring these and other vaccination sites live.
With plans and upcoming contracts in other states PCA’s President & Executive Director, Will Adkins, says that they are well-positioned to continue staffing additional testing and vaccination sites around the country. “These new vaccination sites have been a long time coming and will play an important role in the Covid-19 response effort for these communities.”
“With operations in multiple states and our existing partnerships in combination with our experience we are well-positioned to efficiently assist both government and private companies with their testing and vaccination programs.”
“We can help officials identify and qualify vaccine candidates and offer a complete turnkey solution. That seems to be really important to some of these agencies and emergency response officials we are working with.”
“Our caregivers are excited to be working on these efforts. My team is excited to be a part of this. We are extremely proud and very thankful have a small role in this very important nationwide initiative.”
Pulse Clinical Alliance (PCA) is a Joint Commissioned Certified Clinical Agency based out of Jacksonville, FL. PCA provides a wide array of clinical solutions for their clients in all 50 states and Canada. Those solutions include Clinical Staffing, Workforce Management, Vendor Management, Advisory and MSP services.
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to an ongoing pandemic.
Symptoms of COVID-19 are variable, but often include fever, cough, fatigue, breathing difficulties, and loss of smell and taste. Symptoms begin one to fourteen days after exposure to the virus. Of those people who develop noticeable symptoms, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction). Older people are more likely to have severe symptoms. At least a third of the people who are infected with the virus remain asymptomatic and do not develop noticeable symptoms at any point in time, but they still can spread the disease. Some people continue to experience a range of effects—known as long COVID—for months after recovery, and damage to organs has been observed. Multi-year studies are underway to further investigate the long-term effects of the disease.
The virus that causes COVID-19 spreads mainly when an infected person is in close contact[a] with another person. Small droplets and aerosols containing the virus can spread from an infected person’s nose and mouth as they breathe, cough, sneeze, sing, or speak. Other people are infected if the virus gets into their mouth, nose or eyes. The virus may also spread via contaminated surfaces, although this is not thought to be the main route of transmission. The exact route of transmission is rarely proven conclusively, but infection mainly happens when people are near each other for long enough. People who are infected can transmit the virus to another person up to two days before they themselves show symptoms, as can people who do not experience symptoms. People remain infectious for up to ten days after the onset of symptoms in moderate cases and up to 20 days in severe cases. Several testing methods have been developed to diagnose the disease. The standard diagnostic method is by detection of the virus’ nucleic acid by real-time reverse transcription polymerase chain reaction (rRT-PCR), transcription-mediated amplification (TMA), or by loop-mediated isothermal amplification from a nasopharyngeal swab.
Preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. The use of face masks or coverings has been recommended in public settings to minimise the risk of transmissions. Several vaccines have been developed and several countries have initiated mass vaccination campaigns.
This News Was Shared To Prittle Prattle News Via A Press Release.
By PR Newswire
Also Read:- Upstryve , Medcillary
